XG2002 / Xgene Pharma, RaQualia - LARVOL DELTA

The safety and pharmacokinetics of a novel transient receptor potential melastatin 8 (TRPM8) antagonist, XG2002, in a phase 1 study (AHS 2026) - "Recently, a TRPM8 antagonist (elismetrep) showed positive results in an acute migraine trial. The novel peripheral acting TRPM8 antagonist, XG2002, showed linear systemic exposure following oral dosing, with consistent short Tmax. T1/2 prolonged with increased dose, which forms a basis for options of dose interval. Mild AEs were transient and well tolerated."

Clinical • P1 data • PK/PD data • CNS Disorders • Migraine • TRPM8

A Phase I, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of XG2002 Oral Administration in Healthy Adult Volunteers (ANZCTR) - P1 | N=32 | Recruiting | Sponsor: Xgene Pharmaceutical Pty Ltd | Not yet recruiting ➔ Recruiting | N=48 ➔ 32 | Initiation date: Apr 2024

Enrollment change • Enrollment open • Trial initiation date • Pain